Novantrone Solution For Injection 2Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Novantrone: Solution for injection (2mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

MITOXANTRONE (MYE toe ZAN trone) is a chemotherapy drug. It targets fast dividing cells, like cancer cells, and causes these cells to die. This medicine is used to treat acute nonlymphocytic leukemia (ANLL) and advanced prostate cancer. It is also used to treat certain types of multiple sclerosis.

In-Depth Information
Select a Medication

Novantrone 30mg/15ml Solution for Injection

NDC: 440871530
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Acute Myelogenous Leukemia (AML), Prostate Cancer, Multiple Sclerosis

Sometimes used for but not FDA approved for the following conditions:
Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Acute Lymphocytic Leukemia (ALL), Stem Cell Transplant Preparation, Chronic Lymphocytic Leukemia (CLL), Hepatocellular Cancer, Pleural Effusion

Storage Information
Protect from freezing
Store between 59 to 77 degrees F
Novantrone 30mg/15ml Solution for Injection

Reported Side Effects for Novantrone 30mg/15ml Solution for Injection

Bleeding In The Brain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
<19.0%*
Severity: MODERATE
Onset: DELAYED
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Conjunctivitis Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Kidney Failure Incidence:
<8.0%*
Severity: SEVERE
Onset: DELAYED
Secondary Malignancy Incidence:
0.3-2.8%*
Severity: MODERATE
Onset: DELAYED
Fluid In Lungs Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Intestinal Bleeding Incidence:
2.0-16.0%*
Severity: SEVERE
Onset: DELAYED
Convulsions Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Heart Failure Incidence:
2.3-5.0%*
Severity: SEVERE
Onset: DELAYED
Yellow Skin Incidence:
3.0-7.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
3.0-39.0%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
5.0-75.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
5.0-20.0%*
Severity: MODERATE
Onset: DELAYED
Bleeding Incidence:
5.0-37.0%*
Severity: MODERATE
Onset: EARLY
Infertility Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Depression Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Chills Incidence:
5.0%*
Severity: MILD
Onset: RAPID
Infection Incidence:
5.0-81.0%*
Severity: MILD
Onset: DELAYED
Shortness Of Breath Incidence:
5.0-18.0%*
Severity: MODERATE
Onset: EARLY
Fever Incidence:
6.0-78.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
6.0-13.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Protein In The Urine Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Red Spotted Rash Incidence:
7.0-11.0%*
Severity: MILD
Onset: DELAYED
Low Potassium Levels Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Sexual Desire Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Impotence (erectile Dysfunction) Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Bruise Incidence:
7.0-11.0%*
Severity: MILD
Onset: DELAYED
Mouth Ulcers Incidence:
8.0-29.0%*
Severity: MODERATE
Onset: DELAYED
Back Pain Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
9.0-13.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
9.0-15.0%*
Severity: MILD
Onset: EARLY
Low Blood Sodium Levels Incidence:
9.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
9.0-72.0%*
Severity: MILD
Onset: EARLY
Excessive Sweating Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
10.0-16.0%*
Severity: MODERATE
Onset: DELAYED
Swelling Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: DELAYED
Low Calcium Levels Incidence:
10.0%*
Severity: MODERATE
Onset: DELAYED
Blood In The Urine Incidence:
11.0%*
Severity: MODERATE
Onset: DELAYED
Onycholysis Incidence:
11.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
14.0-47.0%*
Severity: MILD
Onset: EARLY
Weight Loss Incidence:
17.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
20.0-61.0%*
Severity: MILD
Onset: DELAYED
Decreased Appetite Incidence:
22.0-25.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cells Incidence:
23.0-54.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
26.0-76.0%*
Severity: MILD
Onset: EARLY
Increased Blood Sugar Incidence:
31.0%*
Severity: MODERATE
Onset: DELAYED
Feeling Sick Incidence:
34.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
34.0-39.0%*
Severity: MILD
Onset: EARLY
No Menstrual Periods Incidence:
43.0%*
Severity: MILD
Onset: DELAYED
Low Lymphocytes Incidence:
72.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Novantrone

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5